Ohman, E Magnus <br/><br/>
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.  [electronic resource] 

 -  Lancet (London, England)  May 2017 
 - 1799-1808 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1474-547X 
<br/><br/><label>Standard No.: </label>10.1016/S0140-6736(17)30751-1  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acute Coronary Syndrome--drug therapy<br/>Adenosine--administration & dosage<br/>Aged<br/>Aspirin--administration & dosage<br/>Clopidogrel<br/>Coronary Angiography--methods<br/>Double-Blind Method<br/>Drug Therapy, Combination--methods<br/>Electrocardiography--methods<br/>Factor Xa Inhibitors--therapeutic use<br/>Female<br/>Hemorrhage--chemically induced<br/>Humans<br/>Male<br/>Middle Aged<br/>Myocardial Infarction--diagnostic imaging<br/>Platelet Aggregation Inhibitors--therapeutic use<br/>Purinergic P2Y Receptor Antagonists--administration & dosage<br/>Rivaroxaban--administration & dosage<br/>Thrombolytic Therapy--methods<br/>Ticagrelor<br/>Ticlopidine--administration & dosage<br/>Treatment Outcome